GRID2 — Glutamate Ionotropic Receptor Delta Type Subunit 2

GRID2 — Glutamate Ionotropic Receptor Delta Type Subunit 2

<div class="infobox infobox-gene">
<div class="infobox-header">GRID2</div>

Overview

GRID2 is a human gene whose product gRID2 (Glutamate Receptor Ionotropic Delta 2), also known as GluRδ2 or GluD2, is a member of the delta glutamate receptor family with critical roles in cerebellar function, synaptic plasticity, and motor coordination[@yuzaki2020]. Variants in GRID2 have been implicated in Spinocerebellar Ataxia (SCA), Ataxia, Epilepsy. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

GRID2 — Glutamate Ionotropic Receptor Delta Type Subunit 2

<div class="infobox infobox-gene">
<div class="infobox-header">GRID2</div>

Overview

GRID2 is a human gene whose product gRID2 (Glutamate Receptor Ionotropic Delta 2), also known as GluRδ2 or GluD2, is a member of the delta glutamate receptor family with critical roles in cerebellar function, synaptic plasticity, and motor coordination[@yuzaki2020]. Variants in GRID2 have been implicated in Spinocerebellar Ataxia (SCA), Ataxia, Epilepsy. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

<div class="infobox-row"><span>Full Name:</span> Glutamate Ionotropic Receptor Delta Type Subunit 2</div>
<div class="infobox-row"><span>Symbol:</span> GRID2</div>
<div class="infobox-row"><span>Chromosomal Location:</span> 4q22.1</div>
<div class="infobox-row"><span>NCBI Gene ID:</span> <a href="https://www.ncbi.nlm.nih.gov/gene/2895" target="_blank">2895</a></div>
<div class="infobox-row"><span>OMIM:</span> <a href="https://www.omim.org/entry/602368" target="_blank">602368</a></div>
<div class="infobox-row"><span>Ensembl ID:</span> ENSG00000128283</div>
<div class="infobox-row"><span>UniProt:</span> <a href="https://www.uniprot.org/uniprot/Q9ULK2" target="_blank">Q9ULK2</a></div>
<div class="infobox-row"><span>Associated Diseases:</span> [Ataxia](/diseases/ataxia), [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia), [Epilepsy](/diseases/epilepsy), [Huntington's Disease](/diseases/huntingtons-disease), [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)</div>
</div>

Function

GRID2 (Glutamate Receptor Ionotropic Delta 2), also known as GluRδ2 or GluD2, is a member of the delta glutamate receptor family with critical roles in cerebellar function, synaptic plasticity, and motor coordination[@yuzaki2020].

Structure

GRID2 contains:

• Large extracellular N-terminal domain (ATD)
• Ligand-binding domain (LBD)
• Three transmembrane regions
• Long intracellular C-terminal domain

Role in Cerebellar Function

GRID2 is essential for:

Molecular Mechanisms

Synaptic Signaling Cascade

GRID2 mediates synaptic plasticity through a well-characterized signaling cascade:

Downstream Signaling Partners

GRID2 interacts with several key signaling proteins:

• Protein Kinase C (PKC): Key mediator of LTD induction
• CaMKII: Calcium/calmodulin-dependent protein kinase II
• MAP1B: Microtubule-associated protein involved in synaptic plasticity
• Shank2: Scaffold protein at postsynaptic密度

Retrograde Signaling

GRID2 also participates in retrograde signaling to presynaptic terminals[@usui2019]:

• Postsynaptic GRID2 activation triggers release of trophic factors
• Regulates presynaptic release probability
• Important for synaptic maturation and maintenance

Cerebellar Circuit Integration

The cerebellar cortex contains several distinct neuron types that interact with GRID2-expressing Purkinje cells:

| Cell Type | Interaction with GRID2 Pathway |
|-----------|-------------------------------|
| Granule Cells | Provide parallel fiber input to Purkinje cells |
| Basket Cells | Inhibit Purkinje cell soma |
| Stellate Cells | Inhibit Purkinje cell dendrites |
| Golgi Cells | Modulate granule cell activity |
| Deep Cerebellar Nuclei | Receive output from Purkinje cells |

Animal Models

Knockout Studies

• GRID2-null mice: Show severe ataxia, impaired motor learning
• Conditional deletion in Purkinje cells: Recapitulates motor deficits
• Adult-onset deletion: Impairs existing motor memories[@pcp2_cre]

Transgenic Models

• GRID2-overexpression: Causes synaptic abnormalities
• SCA18-model mice: Recapitulate human phenotype

Phenotypic Characteristics

| Model | Behavior | Neuropathology |
|-------|----------|----------------|
| GRID2⁻/⁻ | Severe ataxia, tremor | Impaired PF-PC synapse formation |
| GRID2ᐟᐟ Purkinje | Ataxic gait | Abnormal spine morphology |
| SCA18 KI | Mild-moderate ataxia | Age-dependent Purkinje cell loss |

Disease Associations

Spinocerebellar Ataxia (SCA)

GRID2 mutations cause SCA18, an autosomal recessive disorder[@sca18_2015][@sca18_2019]:

| Feature | Description |
|---------|-------------|
| Inheritance | Autosomal recessive |
| Onset | Childhood to early adulthood |
| Core Symptoms | Progressive cerebellar ataxia, dysarthria, oculomotor abnormalities |
| Additional | Peripheral neuropathy in some cases |
| MRI Findings | Cerebellar atrophy, particularly vermis |

The p.L812P mutation was first identified in a large family with multiple affected individuals demonstrating progressive gait ataxia, dysarthria, and nystagmus[@bauer2012].

Ataxia

GRID2 variants cause various ataxic disorders:

• Early-onset cerebellar ataxia: Often before age 10
• Delayed motor development: Gross motor milestones delayed
• Gait instability: Wide-based, unsteady walking
• Intention tremor: Action tremor affecting coordination

Epilepsy

GRID2 associations with epilepsy[@bauer2012]:

• Generalized epilepsy: Including absence seizures
• Focal seizures: With or without secondary generalization
• Febrile seizures: Particularly in children
• Febrile Seizures Plus (FS+): Extended febrile seizure phenotype

Huntington's Disease

GRID2 expression altered in HD[@hd_striatum]:

• Reduced GRID2 expression in striatum
• May affect cerebellar input to basal ganglia
• Contributes to motor symptom heterogeneity
• Potential modifier of disease progression

Alzheimer's Disease

While not a primary cause, GRID2 may be relevant to AD pathogenesis[@ad_expression]:

• Altered expression of glutamate receptors in AD brain
• GRID2-mediated calcium dysregulation may contribute to excitotoxicity
• Interaction with tau pathology[@tau_relevance]
• Potential therapeutic target for cerebellar symptoms in AD

Autism Spectrum Disorder

GRID2 variants found in ASD[@asd_grid2]:

• Social and communication deficits
• Intellectual disability
• Motor coordination problems (cerebellar dysfunction)
• Often co-occurring with epilepsy

Parkinson's Disease

Emerging evidence suggests GRID2 may be relevant to PD:

• Expression changes in substantia nigra
• Potential interaction with dopaminergic signaling
• May influence cerebellar contributions to PD tremor

Expression

GRID2 shows highly specific expression:

• Cerebellum: Almost exclusively in Purkinje cells
• [Hippocampus](/brain-regions/hippocampus): CA3 pyramidal cells[@yamaguchi2018]
• Olfactory bulb: Mitral cells
• Thalamus: Specific nuclei

Brain Region Distribution

Protein Structure and Function

Domain Architecture

GRID2 belongs to the ionotropic glutamate receptor family but functions as a non-channel-forming receptor:

| Domain | Location | Function |
|--------|----------|----------|
| N-terminal domain (NTD) | Extracellular | Ligand-independent dimerization, subunit assembly |
| Ligand-binding domain (LBD) | Extracellular | Binds glycine/D-serine, induces conformational change |
| Transmembrane domain (TMD) | Membrane | Three helices (M1, M3, M4), M2 forms pore-like structure |
| C-terminal domain (CTD) | Intracellular | PDZ-binding motif, protein interactions, trafficking |

Post-Translational Modifications

GRID2 undergoes several PTMs that regulate its function:

• Phosphorylation: Serine/threonine residues in CTD (PKC, CaMKII targets)
• Palmitoylation: Cysteine residues for membrane anchoring
• Glycosylation: N-linked glycosylation in extracellular domains
• Ubiquitination: For degradation and trafficking regulation

Protein-Protein Interactions

GRID2 interacts with numerous proteins to mediate its functions:

Common Variants

| Variant | Type | Associated Phenotype | Population Frequency |
|---------|------|----------------------|---------------------|
| p.L812P | Missense | SCA18 | Rare |
| p.R443H | Missense | Ataxia | Rare |
| p.D73N | Missense | Epilepsy | Rare |
| p.G700R | Missense | ASD | Rare |
| c.2319-1G>A | Splicing | Ataxia | Rare |
| p.Y506C | Missense | Ataxia, epilepsy | Very rare |
| p.V695M | Missense | Late-onset ataxia | Very rare |

Variant Pathogenesis

• Missense mutations: Often affect ligand binding or trafficking
• Truncating mutations: Lead to complete loss of function
• Splicing mutations: Cause exon skipping or intron retention

Therapeutic Implications

Gene Therapy Approaches

Recent advances in gene therapy offer promising treatment options[@motohashi2023][@konno2020]:

• Serotype: AAV9 or AAV.PHP.B for CNS targeting
• Promoter: Synapsin or Mecp2 for neuron-specific expression
• Route: Intrathecal or intravenous administration

• Wild-type GRID2 delivered to restore function
• Critical timing: Early intervention before irreversible degeneration

• siRNA to silence dominant-negative alleles
• CRISPR-Cas9 to correct pathogenic variants

Small Molecule Approaches

| Target | Strategy | Status |
|--------|----------|--------|
| PKC activators | Enhance LTD signaling | Preclinical |
| mGluR1 modulators | Compensation for GRID2 loss | Investigational |
| Trophic factors | BDNF, GDNF delivery | Preclinical |
| Antioxidants | Reduce oxidative stress | Experimental |

Targeting Downstream Pathways

The GRID2-mediated signaling cascade offers multiple intervention points[@pkctargeting][@camkii_grid2]:

• PKC modulators: Enhance synaptic plasticity
• CaMKII activators: Improve learning and memory
• AMPA receptor modulators: Compensation for altered transmission

Symptomatic Management

• Physical therapy: Maintain motor function
• Occupational therapy: Adaptive strategies
• Speech therapy: For dysarthria
• Seizure control: Antiepileptic medications as needed

Animal Models and Research

Knockout Models

| Model | Phenotype | Research Use |
|-------|-----------|---------------|
| GRID2⁻/⁻ | Severe ataxia, death by P21 | Developmental studies |
| GRID2ᐟᐟ Purkinje | Adult-onset ataxia | Adult function studies |
| GRID2ᐟᐟ forebrain | Learning deficits | Hippocampal function |

Disease Models

• SCA18 knock-in: p.L812P mutation introduced
• Ataxia model mice: Various GRID2 point mutations
• Humanized models: Human GRID2 expressed in mouse brain

Interaction Network

Research Directions

Current Focus Areas

Unanswered Questions

• Why are Purkinje cells specifically vulnerable?
• What determines phenotypic variability?
• Can adult neurons be rescued?
• What is the normal ligand for GRID2?

See Also

• [GRID1](/genes/grid1) — Glutamate Receptor Delta 1
• [GRIA1](/genes/gria1) — AMPA Receptor Subunit 1
• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia) — SCA overview
• [Cerebellum](/brain-regions/cerebellum) — Cerebellum overview

External Links

• [NCBI Gene: GRID2](https://www.ncbi.nlm.nih.gov/gene/2895)
• [UniProt: Q9ULK2](https://www.uniprot.org/uniprot/Q9ULK2)
• [OMIM: 602368](https://www.omim.org/entry/602368)
• [GeneCards: GRID2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRID2)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving GRID2 — Glutamate Ionotropic Receptor Delta Type Subunit 2 discovered through SciDEX knowledge graph analysis: